세계의 재조합형 C 인자 어세이 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Recombinant Factor C Assay Market is presumed to reach the market size of nearly USD 56.2 Million by 2032 from USD 24.73 Million in 2023 with a CAGR of 9.55% under the study period 2024-2032.

Recombinant factor C assay is used to measure the scale of endotoxin exposure or level of pyrogens. It uses a recombinant protein and a small fluorescent peptide, a synthetic alternative to crab lysate, for detection. There are three different specificities of rFC, Enzymatic, Spectral, and Genetic level to better distinguish the impurity present in the sample from other, non-related substances and impurities. Endotoxin testing plays a critical role in the pharmaceutical industry since it ensures that injectable pharmaceutical products and medical devices are safe for human use. The high sensitivity, specificity, and lesser variability of this measurement technique lead to more precise and accurate readings.

MARKET DYNAMICS

The rising need to alleviate the pressures of a growing demand for the Limulus amoebocyte lysate (LAL) assay and the development of alternative endotoxin detection tests like rfC will be the trending factors for the growth of this market. The high accuracy, specificity, robustness, sustainability, lot-to-lot consistency, ease-of-use & a suitable sensitivity range, enhanced endotoxin specificity, and reproducibility of these assays will expand the market across several industries like cosmetics, research, environment, food, and water quality control. The decline in the horseshoe crab population and the threat of their extinction will further propel this market's growth. The main restraining factor for this market's development is the lack of efficacy of rfC compared to traditional methods.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Recombinant Factor C Assay. The growth and trends of Recombinant Factor C Assay industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Recombinant Factor C Assay market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Brand

• PyroGene (PyroGene Bulk rFC (2,880 tests), PyroGene rFC (192 tests))
• EndoNext (EndoZyme II, EndoZyme II GO, EndoLisa)

By End User

• Pharmaceutical Companies
• Biotechnology Companies
• Medical Device Companies
• Contract Research Organizations (CROs)

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Recombinant Factor C Assay market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Recombinant Factor C Assay market include Lonza Group, Hyglos GmbH - A BioMeRieux Company. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. RECOMBINANT FACTOR C ASSAY - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Brand
  • 3.7.2 Market Attractiveness Analysis By End User
  • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL RECOMBINANT FACTOR C ASSAY MARKET ANALYSIS BY BRAND

• 5.1. Overview By Brand
• 5.2. Historical and Forecast Data Analysis By Brand
• 5.3. PyroGene (PyroGene Bulk rFC (2,880 tests), PyroGene rFC (192 tests)) Historic and Forecast Sales By Regions
• 5.4. EndoNext (EndoZyme II, EndoZyme II GO, EndoLisa) Historic and Forecast Sales By Regions

6. GLOBAL RECOMBINANT FACTOR C ASSAY MARKET ANALYSIS BY END USER

• 6.1. Overview By End User
• 6.2. Historical and Forecast Data Analysis By End User
• 6.3. Pharmaceutical Companies Historic and Forecast Sales By Regions
• 6.4. Biotechnology Companies Historic and Forecast Sales By Regions
• 6.5. Medical Device Companies Historic and Forecast Sales By Regions
• 6.6. Contract Research Organizations (CROs) Historic and Forecast Sales By Regions

7. GLOBAL RECOMBINANT FACTOR C ASSAY MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2 North America By Segment Sales Analysis
  • 7.3.3 North America By Country Sales Analysis
  • 7.3.4 United States Sales Analysis
  • 7.3.5 Canada Sales Analysis
  • 7.3.6 Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2 Europe By Segment Sales Analysis
  • 7.4.3 Europe By Country Sales Analysis
  • 7.4.4 United Kingdom Sales Analysis
  • 7.4.5 France Sales Analysis
  • 7.4.6 Germany Sales Analysis
  • 7.4.7 Italy Sales Analysis
  • 7.4.8 Russia Sales Analysis
  • 7.4.9 Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2 Asia Pacific By Segment Sales Analysis
  • 7.5.3 Asia Pacific By Country Sales Analysis
  • 7.5.4 China Sales Analysis
  • 7.5.5 India Sales Analysis
  • 7.5.6 Japan Sales Analysis
  • 7.5.7 South Korea Sales Analysis
  • 7.5.8 Australia Sales Analysis
  • 7.5.9 South East Asia Sales Analysis
  • 7.5.10 Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2 Latin America By Segment Sales Analysis
  • 7.6.3 Latin America By Country Sales Analysis
  • 7.6.4 Brazil Sales Analysis
  • 7.6.5 Argentina Sales Analysis
  • 7.6.6 Peru Sales Analysis
  • 7.6.7 Chile Sales Analysis
  • 7.6.8 Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2 Middle East & Africa By Segment Sales Analysis
  • 7.7.3 Middle East & Africa By Country Sales Analysis
  • 7.7.4 Saudi Arabia Sales Analysis
  • 7.7.5 UAE Sales Analysis
  • 7.7.6 Israel Sales Analysis
  • 7.7.7 South Africa Sales Analysis
  • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE RECOMBINANT FACTOR C ASSAY COMPANIES

• 8.1. Recombinant Factor C Assay Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9. COMPANY PROFILES OF RECOMBINANT FACTOR C ASSAY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Lonza Group
  • 9.3.1 Company Overview
  • 9.3.2 Company Revenue
  • 9.3.3 Products
  • 9.3.4 Recent Developments
• 9.4. Hyglos GmbH - A BioMeRieux Company
  • 9.4.1 Company Overview
  • 9.4.2 Company Revenue
  • 9.4.3 Products
  • 9.4.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies